Doug Witt | CEO
Unison Medicines

Doug Witt is the CEO and cofounder of Unison Medicines, a discovery-stage pharmaceutical company focused on solving the Anti-Microbial Resistance crisis.  Unison discovers novel small molecules which block bacterial DNA damage repair and associated stress responses.  Previously Doug worked at Amgen as an Early Operations Leader for an early stage asset and a chemical engineer where he led upstream large molecule manufacturing engineering through multiple product launches and FDA approvals. Prior to Amgen, Doug served as a submarine officer in the US Navy, where he led robotics technology development, and held key leadership roles during five deployments aboard the USS ALABAMA BLUE, a high-performing $5B nuclear-powered ballistic missile submarine carrying $2B in weapons and 150 sailors. Doug is a graduate of the Leaders for Global Operations program at MIT, earning an MBA and an engineering masters (focus on genetics).  He studied chemistry and Chinese at Stanford as an undergraduate.